Exicure, Inc. received a Nasdaq notice for delayed filing of its Q1 2026 Form 10-Q due to changes in financial staff and procedures. The company filed the report on May 29, 2026, and believes it has restored compliance with Nasdaq rules. Exicure is currently exploring strategic options following restructuring and clinical activity suspension, focusing on therapies for hematologic diseases. This filing issue is resolved, allowing the company to continue its operations without Nasdaq compliance concerns.
Carahsoft Technology Corp. is hosting the Annual GovExperience Summit on June 2, 2026, in Reston, Virginia, focusing on improving government service delivery and customer experience through emerging technologies. The event gathers leaders from federa...
Kuehn Law, PLLC is investigating whether Vistagen Therapeutics' officers and directors breached their duties by misrepresenting risks in their Social Anxiety Disorder clinical trials. The lawsuit claims insiders failed to disclose high placebo respon...
Anthropic has confidentially submitted a draft registration for an IPO, entering the public market race shortly after SpaceX's filing. While SpaceX focuses on space infrastructure and satellite communications, Anthropic offers investors exposure to f...
This week could be the busiest for IPOs since 2021, with five companies going public that touch on popular Wall Street themes like quantum computing, defense, digital advertising, AI infrastructure, and energy. Notable IPOs include Liftoff Mobile, Ap...
As summer begins, North Texas faces a surge in child hunger due to loss of school meals. WFAA, North Texas Food Bank, and Tarrant Area Food Bank are hosting the Nourish North Texas Telethon on June 11 to raise funds for at least one million meals for...
